The company's principal activity is to develop a new generation of opioid painkillers. the company (a development stage company) has four pain killers in various stages of phase ii clinical trials. each product is a proprietary combination of opioids. the product consists of two components: an opioid agonist, such as morphine and a low dose opioid antagonist such as naltrexone or naloxone. the opioid agonist is a drug that is used to block the pain and an opioid antagonist is a compound that blocks pain relief.